PlainPharmaWatch

CMS Open Payments · Program Year 2024

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. reported $23,555,020.52 across General Payments, Research, and Ownership to 79,802 physicians and teaching hospitals across 80,352 transactions.

$23.6M
All-tracks total
80,352
Transactions
79,802
Recipients
+$3.5M
General Payments vs PY2023

Axsome Therapeutics, Inc. reported $23,555,020.52 across all CMS Open Payments tracks (General + Research + Ownership) to 79,802 physicians and teaching hospitals in Program Year 2024 - ranking #84 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $12,229,272.83, averaging $295.17 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer axsome-therapeutics-inc Axsome Therapeutics, Inc.

$23.6M · #84/1,925 · 0.2% industry · PY2024

  • TOT $23.6M
  • RANK #84
  • SHARE 0.2%
  • TXN 80,352
  • RCP 79,802
  • CAT 6
  • GEN $12.2M
  • ΔGEN +$3.5M
  • TOP1 2.0%
  • PY 2024

Nearest volume peer: Alcon Research LLC ($23.7M)

Regeneron Healthcare Solutio…$24.7MGrace Medical, Inc.$24.1MAlcon Research LLC$23.7MAxsome Therapeutics, Inc. (t…$23.6MBausch Health US, LLC$22.5M
All-tracks payment totals near Axsome Therapeutics, Inc. (CMS Open Payments PY2024)

Axsome Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Axsome Therapeutics, Inc.'s CMS-reported General Payments increased by $3.5M (+39.8%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: AXSOME THERAPEUTICS, INC.PY2023: AXSOME THERAPEUTICS, INC.PY2024: Axsome Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$8.7MPY2024$12.2M
PY2023
$8,747,928.20
PY2024
$12,229,272.83

What the Data Shows for Axsome Therapeutics, Inc.

Averaging $293.15 per transaction and $295.17 per recipient, Axsome Therapeutics, Inc.'s Program Year 2024 total comes to $23,555,020.52 across 80,352 transactions and 79,802 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #84 of 1,925 companies, representing 0.2% of all industry payments reported nationwide for the year.

The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $8.7M, accounting for 70.8% of this company's General Payments and 3,538 transactions.

General Payment Breakdown by Type

"Consulting Fee" leads Axsome Therapeutics, Inc.'s 6-category general-payment breakdown at $8.7M, 70.8% of the reported total.

Axsome Therapeutics, Inc. reports 6 general-payment categories - the top three are Consulting Fee (70.8%), Food and Beverage (19.5%), and Travel and Lodging (7.7%). The remaining 3 categories make up 2.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Axsome Therapeutics, Inc. divides its payments

How the reported total splits across payment categories

1. Consulting Fee$8.7M2. Food and Beverage$2.4M3. Travel and Lodging$945.4K4. Compensation for Faculty …$239.3K5. Education$4.2K6. Space Rental or Facility …$3.5K
Payment Type Amount Transactions
Consulting Fee $8.7M 3,538
Food and Beverage $2.4M 72,011
Travel and Lodging $945.4K 3,718
Compensation for Faculty or Speaker (Medical Education) $239.3K 116
Education $4.2K 418
Space Rental or Facility Fees $3.5K 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $889,273.08 (7.3%) of $12,229,272.83 in this company's General Payments records across 27,135 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Axsome Therapeutics, Inc.

The five named recipients with the highest reported General Payments from this company

Leon Rosenberg$249.4KGregory Mattingley$175.3KScott Wiener$162.4KCraig Chepke$152.3KAndrew Cutler$149.9K
  1. 1

    Leon Rosenberg

    $249,399.95 across 22 reported transactions

  2. 2

    Gregory Mattingley

    $175,349.15 across 164 reported transactions

  3. 3

    Scott Wiener

    $162,397.43 across 234 reported transactions

  4. 4

    Craig Chepke

    $152,275.59 across 118 reported transactions

  5. 5

    Andrew Cutler

    $149,850.96 across 133 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Axsome Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Axsome Therapeutics, Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Axsome Therapeutics, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Axsome Therapeutics, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.